rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-631-636rsp-2960Research ArticleПЕРЕДОВАЯLEADING ARTICLEХронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фенотипомChronic Fibrosing Interstitial Lung Disease with Progressive PhenotypeАнаньеваЛ. П.AnanievaL. P.

115522, Москва, Каширское шоссе, 34а

Lidiya P. Ananieva

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

119991, Москва, ул. Трубецкая, 8, стр. 2

Sergey N. Avdeev

119991, Moscow, Trubetskaya str., 8, building 2

ТюринИ. Е.TyurinI. Е.

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Igor Е. Tyurin

125993, Moscow, Barrikadnaya str., 2/1, building 1

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. М.

115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Alexander М. Lila

115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1

https://orcid.org/0000-0002-3235-1425ЗагребневаА. И.ZagrebnevaA. I.

117997, Москва, ул. Островитянова, 1

Alena I. Zagrebneva

117997, Moscow, Ostrovitianova str., 1

https://orcid.org/0000-0003-2427-4148МаслянскийА. Л.MaslyanskiyА. L.

197341, Санкт-Петербург, ул. Аккуратова, 2

Alexey L. Maslyanskiy

197341, Saint Petersburg, Akkuratova str., 2

https://orcid.org/0000-0001-5444-5943ТерпигоревС. А.TerpigorevS. A.

129110, Москва, ул. Щепкина 61/2, корп. 1

Stanislav А. Terpigorev

129110, Moscow, Shchepkina, 61/2, korpus

https://orcid.org/0000-0002-2985-3379СтепанянИ. В.StepanyanI. V.

107564, Москва, Яузская аллея, 2

Igor V. Stepanyan

107564, Moscow, Yauzkaya av., 2

https://orcid.org/0000-0002-8379-2511ЛашинаЕ. Л.LashinaE. L.

105275, Москва, Проспект Буденного, 31

Elena L. Lashina

105275, Moscow, Budennogo avenue, 31

https://orcid.org/0000-0002-7489-3089ВасильеваО. В.VasilievaO. V.

117997, Москва, ул. Островитянова, 1

Olga V. Vasilieva

117997, Moscow, Ostrovitianova str., 1

https://orcid.org/0000-0002-0882-2936ЛукинаО. С.LukinaO. S.

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Olga S. Lukina

197022, Saint Petersburg, L’va Tolstogo str., 6-8

https://orcid.org/0000-0002-3952-6865ПершинаЕ. С.PershinaE S.

117049, Москва, Ленинский просп., 8

Ekaterina S. Pershina

117049, Moscow, Leninskiy prospect, 8

https://orcid.org/0000-0002-7410-9784КлименкоА. А.KlimenkoА. А.

117997, Москва, ул. Островитянова, 1

Alesya А. Klimenko

117997, Moscow, Ostrovitianova str., 1

https://orcid.org/0000-0003-4669-1006ШостакН. А.ShostakN. A.

117997, Москва, ул. Островитянова, 1

Nadezhda А. Shostak

117997, Moscow, Ostrovitianova str., 1

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeniy Nasonov

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2

nasonov@irramn.ruФГБНУ Научноисследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФРоссияI.M. Sechenov First Moscow State Medical University (Sechenovskiy University)Russian FederationФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования МЗ РФРоссияRussian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования МЗ РФРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО Российский Национальный Исследовательский Медицинский Университет им. Н.И. Пирогова МЗ РФРоссияN.I. Pirogov Russian National Research Medical UniversityRussian FederationФГБУ Национальный медицинский исследовательский центр имени В.А. Алмазова МЗ РФРоссияAlmazov National Medical Research CentreRussian FederationГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical Institute (“MONIKI”)Russian FederationФГБНУ Центральный научно-исследовательский институт туберкулезаРоссияCentral Scientific Research Institute of TuberculosisRussian FederationФБГНУ Научноисследовательский институт медицины труда имени академика Н.Ф. ИзмероваРоссияScientific Research Institute of Occupational Medicine named after N.F. IzmerovRussian FederationФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова МЗ РФРоссияPavlov First Saint Petersburg State Medical UniversityRussian FederationГБУЗ Городская клиническая больница №1 им. Н.И. Пирогова Департамента здравоохранения города МосквыРоссияCity Clinical Hospital N 1 named after N.I. Pirogov of Moscow Department of HealthcareRussian FederationФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФРоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)Russian Federation202013012021586631636Copyright © Ананьева Л.П., Авдеев С.Н., Тюрин И.Е., Лила А.М., Загребнева А.И., Маслянский А.Л., Терпигорев С.А., Степанян И.В., Лашина Е.Л., Васильева О.В., Лукина О.С., Першина Е.С., Клименко А.А., Шостак Н.А., Насонов Е.Л., 20212021Ананьева Л.П., Авдеев С.Н., Тюрин И.Е., Лила А.М., Загребнева А.И., Маслянский А.Л., Терпигорев С.А., Степанян И.В., Лашина Е.Л., Васильева О.В., Лукина О.С., Першина Е.С., Клименко А.А., Шостак Н.А., Насонов Е.Л.Ananieva L.P., Avdeev S.N., Tyurin I.Е., Lila A.М., Zagrebneva A.I., Maslyanskiy А.L., Terpigorev S.A., Stepanyan I.V., Lashina E.L., Vasilieva O.V., Lukina O.S., Pershina E.S., Klimenko А.А., Shostak N.A., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2960

Проблема фиброзирующих интерстициальных заболеваний легких (ИЗЛ) объединяет специалистов разных областей: пульмонологов, рентгенологов, терапевтов, ревматологов, профпатологов и др. Современные достижения в изучении фиброзирующих ИЗЛ, связанные с разработкой иммунологических и молекулярнобиологических методов определения биомаркеров, новых принципов имидж-диагностики патологии легких, поиском новых терапевтических «мишеней», диктуют необходимость интеграции знаний специалистов различных областей медицины для совершенствования алгоритмов фармакотерапии, направленных на подавление прогрессирования фиброза легких при ИЗЛ, улучшение качества и увеличение продолжительности жизни пациентов.

The problem of fibrosing interstitial lung diseases (ILDs) unites specialists from different areas: pulmonologists, radiologists, therapists, rheumatologists, occupational doctors and others. Actual achievements in studying fibrosing ILDs which are connected with development of immunology and molecular biological methods for the determination of biomarkers, new principles of image-diagnostics of lung pathology, search of new therapeutic “targets”, dictate the necessity of integration of knowledge by specialists from different areas of medicine for improvement pharmacotherapy algorithms. These algorithms directed to decrease fibrosis progression in ILDs, improve quality and increase lifespan of the patients.

интерстициальные заболевания легкихиммуновоспалительные ревматические заболеванияантифибротическая терапиянинтеданибinterstitial lung diseasesimmune-inflammatory rheumatic diseasesantifibrotic therapynintedanibReferencesWijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968. DOI: 10.1056/NEJMra2005230Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968. DOI: 10.1056/NEJMra2005230Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. DOI: 10.1186/s12931-020-1296-3Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. DOI: 10.1186/s12931-020-1296-3George PM, Spagnolo P, Kreuter M, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. DOI: 10.1016/S2213-2600(20)30355-6George PM, Spagnolo P, Kreuter M, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. DOI: 10.1016/S2213-2600(20)30355-6Vancheri C, Basile A. Multidisciplinary approach to interstitial lung diseases: Nothing is better than all of us together. Diagnostics (Basel). 2020;10(7):488. DOI: 10.3390/diagnostics10070488Vancheri C, Basile A. Multidisciplinary approach to interstitial lung diseases: Nothing is better than all of us together. Diagnostics (Basel). 2020;10(7):488. DOI: 10.3390/diagnostics10070488Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med (Lausanne). 2019;6:246. DOI: 10.3389/fmed.2019.00246Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med (Lausanne). 2019;6:246. DOI: 10.3389/fmed.2019.00246Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur Resp Rev. 2017;26(144):170008. DOI: 10.1183/16000617.0008-2017Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur Resp Rev. 2017;26(144):170008. DOI: 10.1183/16000617.0008-2017Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Resp Revc. 2018;27(150):180073. DOI: 10.1183/16000617.0073-2018Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Resp Revc. 2018;27(150):180073. DOI: 10.1183/16000617.0073-2018Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56-69. DOI: 10.1016/j.mam.2018.08.004Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56-69. DOI: 10.1016/j.mam.2018.08.004Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. DOI: 10.1080/03007995.2019.1647040Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. DOI: 10.1080/03007995.2019.1647040Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572. DOI: 10.1016/S2213-2600(14)Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572. DOI: 10.1016/S2213-2600(14)Kolb M, Vas;ikov;i M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. DOI: 10.1186/s12931-019-1022-1Kolb M, Vas;ikov;i M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. DOI: 10.1186/s12931-019-1022-1Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоимунные ревматические заболевания - проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;(2):169-182. DOI: 10.15690/vramn.v70i2.1310Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases - problems of immunopathology and personalized treatment. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;(2):169-182 (In Russ.)]. DOI: 10.15690/vramn.v70i2.1310Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. DOI: 10.1016/S0140-6736(13)61499-3Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. DOI: 10.1016/S0140-6736(13)61499-3Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69-82. DOI: 10.1080/1744666X.2018.1411190Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69-82. DOI: 10.1080/1744666X.2018.1411190Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673-2681. DOI: 10.1007/s10067-019-04720-0Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673-2681. DOI: 10.1007/s10067-019-04720-0Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel). 2020;10(4):208. DOI: 10.3390/diagnostics10040208Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel). 2020;10(4):208. DOI: 10.3390/diagnostics10040208Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. DOI: 10.1016/S2213-2600(19)30480-1Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. DOI: 10.1016/S2213-2600(19)30480-1Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255-270. DOI: 10.1055/s-0039-1685187Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255-270. DOI: 10.1055/s-0039-1685187Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med (Lausanne). 2020;6:326. DOI: 10.3389/fmed.2019.00326Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med (Lausanne). 2020;6:326. DOI: 10.3389/fmed.2019.00326Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55. DOI: 10.1016/j.jaut.2019.04.001Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55. DOI: 10.1016/j.jaut.2019.04.001Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-572. DOI: 10.1016/j.ccm.2019.05.004Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-572. DOI: 10.1016/j.ccm.2019.05.004Gonzdlez-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: A case report and literature review. Rheumatol Int. 2018;38(7):1293-1296. DOI: 10.1007/s00296-018-3991-7Gonzdlez-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: A case report and literature review. Rheumatol Int. 2018;38(7):1293-1296. DOI: 10.1007/s00296-018-3991-7Ciang NC, Pereira N, Isenberg DA. Mixed connective tissue disease - enigma variations? Rheumatology (Oxford). 2017;56(3):326-333. DOI: 10.1093/rheumatology/kew265Ciang NC, Pereira N, Isenberg DA. Mixed connective tissue disease - enigma variations? Rheumatology (Oxford). 2017;56(3):326-333. DOI: 10.1093/rheumatology/kew265Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501-518. DOI: 10.1016/j.ccm.2019.05.001Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501-518. DOI: 10.1016/j.ccm.2019.05.001Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: Focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-1554. DOI: 10.1002/art.40574Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: Focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-1554. DOI: 10.1002/art.40574Bendstrup E, M0ller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;8(12):2038. DOI: 10.3390/jcm8122038Bendstrup E, M0ller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;8(12):2038. DOI: 10.3390/jcm8122038Wu EK, Ambrosini RD, Kottmann RM, et al. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15(4):277-289. DOI: 10.2174/1573397115666190116102451Wu EK, Ambrosini RD, Kottmann RM, et al. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15(4):277-289. DOI: 10.2174/1573397115666190116102451George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020;8(8):750-752. DOI: 10.1016/S2213-2600(20)30222-8Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020;8(8):750-752. DOI: 10.1016/S2213-2600(20)30222-8Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. DOI: 10.1016/j.mayocp.2018.09.002Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. DOI: 10.1016/j.mayocp.2018.09.002Акулкина ЛА, Бровко МЮ, Шоломова ВИ, и др. Интерстициальная пневмония с аутоиммунными признаками (ИПАП): мультидисциплинарный диагноз в пульмонологии и ревматологии. Клиническая фармакология и терапия. 2018;18(27):5-10.Akulkina LA, Brovko MYu, Sholomova VI, et al. Interstitial pneumonia with autoimmune features (IPAF): multidisciplinary diagnosis in pulmonology and rheumatology. Klinicheskaya farmakologiya I terapiya = Clinical Pharmacology and Therapy Journal. 2018;18(27):5-10 (In Russ.).Graney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16(5):525-533. DOI: 10.1513/AnnalsATS.201808-565CMEGraney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16(5):525-533. DOI: 10.1513/AnnalsATS.201808-565CMEWilfong EM, Lentz RJ, Guttentag A, et al. Interstitial pneumonia with autoimmune features: An emerging challenge at the intersection of rheumatology and pulmonology. Arthritis Rheumatol. 2018;70(12):1901-1913. DOI: 10.1002/art.40679Wilfong EM, Lentz RJ, Guttentag A, et al. Interstitial pneumonia with autoimmune features: An emerging challenge at the intersection of rheumatology and pulmonology. Arthritis Rheumatol. 2018;70(12):1901-1913. DOI: 10.1002/art.40679Adegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580-588. DOI: 10.1513/AnnalsATS.201807-443OCAdegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580-588. DOI: 10.1513/AnnalsATS.201807-443OCWollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. DOI: 10.1183/13993003.001612019Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. DOI: 10.1183/13993003.001612019Landi C, Bergantini L, Cameli P, et al. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci Rep. 2020;10:9378. DOI: 10.1038/s41598-020-66296-zLandi C, Bergantini L, Cameli P, et al. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci Rep. 2020;10:9378. DOI: 10.1038/s41598-020-66296-zRicheldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Erratum in: N Engl J Med. 2015;373(8):782. DOI: 10.1056/NEJMoa1402584Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Erratum in: N Engl J Med. 2015;373(8):782. DOI: 10.1056/NEJMoa1402584Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478-1484. DOI: 10.1136/annrheumdis-2020-217331Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478-1484. DOI: 10.1136/annrheumdis-2020-217331Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. DOI: 10.1056/NEJMoa1908681Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. DOI: 10.1056/NEJMoa1908681Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9Авдеев СН, Ананьева ЛП, Жиляев ЕВ, и др. Резолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва). Современная ревматология. 2020;14(1):125-128. DOI: 10.14412/1996-7012-2020-1-125-128.Avdeev SN, Ananyeva LP, Zhilyaev EV, et al. The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019). Modern Rheumatology Journal. 2020;14(1):125-128 (In Russ.). DOI: 10.14412/1996-7012-2020-1-125-128.Sinha A, Patel AS, Siegert RJ, et al. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363. DOI: 10.1136/bmjresp-2018-000363Sinha A, Patel AS, Siegert RJ, et al. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363. DOI: 10.1136/bmjresp-2018-000363Liu R, Lei C, Liao X, et al. Semi-quantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19. Radiol Infect Dis. 2020;7(3):114-122. DOI: 10.1016/j.jrid.2020.07.003Liu R, Lei C, Liao X, et al. Semi-quantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19. Radiol Infect Dis. 2020;7(3):114-122. DOI: 10.1016/j.jrid.2020.07.003

The authors declare that there are no conflicts of interest present.